Elafibranor Interrupts Adipose Dysfunction-mediated Gut and Liver Injury in Mice with Alcoholic Steatohepatitis

Conclusions : Altogether, these findings demonstrated that the PPARα/ agonist, elafibranor, decreased the severity of liver injury by restoration of alcohol-suppressed AT autophagy function and by decreasing the release of apoptotic markers, inflammatory cytokines and FFA, thereby reducing intestinal epithelium disruption and liver inflammation/apoptosis/steatosis in ASH mice. These data suggest that dual PPAR agonists can serve as potential therapeutic agents for the management of ASH.

Source: Clinical Science - January 2, 2019 Category: Biomedical Science Authors: Li, T.-H., Yang, Y.-Y., Huang, C.-C., Liu, C.-W., Tsai, H.-C., Lin, M.-W., Tsai, C.-Y., Huang, S.-F., Wang, Y.-W., Lee, T.-Y., Huang, Y.-H., Hou, M.-C., Lin, H.-C. Tags: PublishAheadOfPrint Source Type: research